Comerica Bank Madrigal Pharmaceuticals, Inc. Transaction History
Comerica Bank
- $25 Billion
- Q3 2024
A detailed history of Comerica Bank transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Comerica Bank holds 683 shares of MDGL stock, worth $200,556. This represents 0.0% of its overall portfolio holdings.
Number of Shares
683
Previous 621
9.98%
Holding current value
$200,556
Previous $173,000
16.76%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MDGL
# of Institutions
295Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$728 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$600 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$596 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$585 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$580 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.02B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...